Ben Leu starts to deliver drugs in the Anderson Lab
/Our beloved Ben Leu will start his new career in drug delivery as part of our colleague Dan Anderson’s lab. Go Ben, and remember that we have the good beer.
Our beloved Ben Leu will start his new career in drug delivery as part of our colleague Dan Anderson’s lab. Go Ben, and remember that we have the good beer.
Target identification methods ain’t got nothing on you. Congratulations from all your friends in the lab and beyond. We are proud of you hard work, dedication, intensity, and collegiality. Cullinan Oncology will be luck to have you on their team in 2023. P.S. you win the award for the best champagne bottle popper in lab history!
Read about my path to MIT and the overarching goals of the group in this MIT News article.
https://news.mit.edu/2022/tenured-engineers-1024
The Siebel Scholars Foundation announced the recipients of the 2023 Siebel Scholars award. Our very own Catherine Henry is a worthy recipient!
Now in its 22nd year, the Siebel Scholars program annually recognizes nearly 100 exceptional students commitment to academics and influencing future society. http://ow.ly/jC2f50KQAmM
Congratulations to Catherine and her talented scholar cohort!
The lab celebrated the end of Huarui’s tenure at MIT with a late summer lunch at Shy Bird in Kendall Square (not a cloud in the sky). She’ll be joining Maddy Henley at Foghorn Therapeutics, just down the road, to fight the good fight against diseases with aberrant chromatin regulation. Good luck!
Our collaborative work with the Hammond Lab and the Broad Institute around NanoPRISM was recently published in Science and covered in MIT News:
https://news.mit.edu/2022/how-different-cancer-cells-respond-drug-delivering-nanoparticles-0721
It is with great pleasure to announce that Leyna Duong is a recipient of the 2022 Department of Chemistry Research Award for outstanding achievement in undergraduate research. We know you’ll tackle grad school with ease!
The Koehler Lab aims to innovate in the earliest stages of drug discovery by building chemical tools or technologies to assist in the process of target validation and by expanding the repertoire of protein targets that are considered to be druggable. We focus primarily on building chemical tools and methods for studying temporal aspects of transcriptional regulation in development and disease with a focus on cancer.
The Koehler Lab is supported through the generosity of our public and private funding partners.
We will gladly accommodate requests for greater accessibility of public content.